From genome-wide association studies to etiology: Probing autoimmunity genes by RNAi

Trends in Molecular Medicine

Volumn 17, Issue 11, 2011, Pages 634-640

  Kissler, Stephan ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCUS; GENE TECHNOLOGY; GENETIC ASSOCIATION; GENETIC MANIPULATION; GENETIC MODEL; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; NONHUMAN; REVIEW; RNA INTERFERENCE; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; GENE KNOCKDOWN TECHNIQUES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA INTERFERENCE; RNA SPLICING;

EID: 80755133434     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2011.06.006     Document Type: Review

References (61)

1. Progress in Autoimmune Diseases Research, Report to Congress 2005, The Autoimmune Diseases Coordinating Committee, National Institutes of Health, p. 18.
2. Smith J.G., Newton-Cheh C. Genome-wide association study in humans. Methods Mol. Biol. 2009, 573:231-258.
3. Freedman M.L., et al. Principles for the post-GWAS functional characterization of cancer risk loci. Nat. Genet. 2011, 43:513-518.
4. Fire A., et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
5. McDevitt H.O., Bodmer W.F. HL-A, immune response genes, and disease. Lancet 1974, 7869:1269-1275.
6. Nerup J., et al. HL-A antigens and diabetes mellitus. Lancet 1974, 7885:864-866.
7. Bell G.I., et al. A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes 1984, 33:176-183.
8. Nistico L., et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum. Mol. Genet 1996, 5:1075-1080.
9. Bottini N., et al. A functional variant of lymphoid tyrosine phosphatase is associated with type 1 diabetes. Nat. Genet. 2004, 36:337-338.
10. Vella A., et al. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am. J. Hum. Genet. 2005, 76:773-779.
11. Lander E.S. Initial impact of the sequencing of the human genome. Nature 2011, 470:187-197.
12. International HapMap Consortium The International HapMap project. Nature 2003, 426:789-796.
13. Hardenbol P., et al. Highly multiplexed molecular inversion probe genotyping: over 10,000 targeted SNPs genotyped in a single tube assay. Genome Res. 2005, 15:269-275.
14. Baranzini S.E. The genetics of autoimmune diseases: a networked perspective. Curr. Opin. Immunol. 2009, 21:596-605.
15. Hindorff L.A., et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:9362-9367.
16. MacArthur D.G., Tyler-Smith C. Loss-of-function variants in the genomes of healthy humans. Hum. Mol. Genet. 2010, 19:R125-R130.
17. Kawamata M., Ochiya T. Gene-manipulated embryonic stem cells for rat transgenesis. Cell. Mol. Life Sci. 2011, 68:1911-1915.
18. Brand D.D. Rodent models of rheumatoid arthritis. Comp. Med. 2005, 55:114-122.
19. Morel L., Wakeland E.K. Susceptibility to lupus nephritis in the NZB/W model system. Curr. Opin. Immunol. 1998, 10:718-725.
20. Anderson M.S., Bluestone J.A. The NOD mouse: a model of immune dysregulation. Annu. Rev. Immunol. 2005, 23:447-485.
21. Nichols J., et al. Validated germline-competent embryonic stem cell lines from nonobese diabetic mice. Nat. Med. 2009, 15:814-818.
22. Ridgway W.M., et al. New tools for defining the 'genetic background' of inbred mouse strains. Nat. Immunol. 2007, 8:669-673.
23. Hultgren B., et al. Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice. Diabetes 1996, 45:812-817.
24. Wang B., et al. Interferon-gamma impacts at multiple points during the progression of autoimmune diabetes. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:13844-13849.
25. Serreze D.V., et al. Interferon-gamma receptor signaling is dispensable in the development of autoimmune type 1 diabetes in NOD mice. Diabetes 2000, 49:2007-2011.
26. Fossati-Jimack L., et al. Regulation of B cell tolerance by 129-derived chromosome 1 loci in C57BL/6 mice. Arthritis Rheum. 2008, 58:2131-2141.
27. Peng S., et al. A transgenic approach for RNA interference-based genetic screens in mice. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:2252-2256.
28. Kissler S., et al. In vivo RNA interference demonstrates a role for Nramp1 in modifying susceptibility to type 1 diabetes. Nat. Genet. 2006, 38:479-483.
29. Chen Z., et al. Modeling CTLA4-linked autoimmunity with RNA interference in mice. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:16400-16405.
30. Herold M.J., et al. Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:18507-18512.
31. Wang J., et al. IL-2 and its high-affinity receptor: genetic control of immunoregulation and autoimmunity. Semin. Immunol. 2009, 21:363-371.
32. Sadlack B., et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993, 75:253-261.
33. Dendrou C.A., et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat. Genet. 2009, 41:1011-1015.
34. Yamanouchi J., et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat. Genet. 2007, 39:329-337.
35. Hemann M.T., et al. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat. Genet. 2003, 33:396-400.
36. Sharp P.A. The discovery of split genes and RNA splicing. Trends Biochem. Sci. 2005, 30:279-281.
37. Wang E.T., et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008, 456:470-476.
38. Vaidya B., Pearce S. The emerging role of the CTLA-4 gene in autoimmune endocrinopathies. Eur. J. Endocrinol. 2004, 150:619-626.
39. Tivol E.A., et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3:541-547.
40. Waterhouse P., et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995, 270:985-988.
41. Ueda H., et al. Association of the T cell regulatory gene CTLA-4 with susceptibility to autoimmune disease. Nature 2003, 423:506-511.
42. Gerold K.D., et al. The soluble CTLA-4 splice variant protects from type 1 diabetes and potentiates regulatory T cell function. Diabetes 2011, 60:1955-1963.
43. Zheng X., et al. Treatment of autoimmune arthritis using RNA interference-modulated dendritic cells. J. Immunol. 2010, 184:6457-6464.
44. Zheng X., et al. RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis. Arthritis Res. Ther. 2010, 12:R13.
45. Courties G., et al. In vivo RNAi-mediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells. Blood 2010, 116:3505-3516.
46. Yamada A., et al. Cathepsin L inhibition prevents murine autoimmune diabetes via suppression of CD8+ T cell activity. PloS ONE 2010, 5:e12894.
47. Yang Y., et al. Silencing Nogo-A promotes functional recovery in demyelinating disease. Ann. Neurol. 2010, 67:498-507.
48. Shim M.S., Kwon Y.J. Efficient and targeted delivery of siRNA in vivo. FEBS J. 2010, 277:4814-4827.
49. Wiznerowicz M., et al. Tuning silence: conditional systems for RNA interference. Nat. Methods 2006, 3:682-688.
50. Premsirut P.K., et al. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 2011, 145:145-158.
51. Hayashi S., McMahon A.P. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev. Biol. 2002, 244:305-318.
52. Elbashir S.M., et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
53. Brummelkamp T.R., et al. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296:550-553.
54. Brummelkamp T.R., et al. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002, 2:243-247.
55. Abbas-Terki T., et al. Lentiviral-mediated RNA interference. Hum. Gene Ther. 2002, 13:2197-2201.
56. Lois C., et al. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002, 295:868-872.
57. Rubinson D.A., et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet. 2003, 33:401-406.
58. Tiscornia G., et al. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:1844-1848.
59. Fellmann C., et al. Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Mol. Cell 2011, 41:733-746.
60. Birmingham A., et al. 3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat. Methods 2006, 3:199-204.
61. Baup D., et al. Variegation and silencing in a lentiviral-based murine transgenic model. Transgenic Res. 2010, 19:399-414.